Breast Cancer Clinical Trial
Official title:
OctavaPink® For Dense Breast After Negative Mammography
The OctavaPink test is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women for whom screening or diagnostic mammography findings are normal or benign (BIRADS assessment category 1 or 2) and breast tissue is dense (BIRADS composition/density 3 or 4). The device is intended to increase breast cancer detection in the described patient population. Based upon the result of OctavaPink, the patient will be further evaluated by their physician.
This is a multicenter, prospective study containing 3 parts:
Part 1 consists of Part 1A (optimization/training) and Part 1B (evaluation/testing) as
follows:
Part 1A will optimize the OctavaPink test for women with dense breast tissue, and will not
affect the treatment of the participants. Part 1A is an internal part done by EventusDx and
no statistical evaluation is needed.
Objectives: To optimize the OctavaPink test, with the target of ≥95% specificity and ≥70%
sensitivity.
Part 1B will assess the properties of the OctavaPink test using cases and controls obtained
via the same criteria as in Part 1A. The sensitivity and specificity of the OctavaPink test
must be confirmed as sufficiently high in samples in which EventusDx is blind to
case/control status before using the test to affect clinical management of patients.
Objectives:
(i) To obtain a sensitivity estimate ≥60% with 95% CI lower limit ≥50% in the whole group of
cancer cases (DCIS, IDC and ILC); also to obtain a sensitivity estimate with the same
properties in the subset of cases with invasive cancer (IDC and ILC).
(ii) To obtain a specificity estimate ≥90% in controls with 95% CI lower limit ≥85%.
Part 2 will examine the yield of cancer detection by MRI/biopsy among women who have a
positive OctavaPink test result in the dense breast negative mammography population.
Objectives:
(i) To compare the yield of cancer detection via MRI/biopsy among women with a positive
OctavaPink test versus a negative OctavaPink test result.
(ii) To estimate the proportion of patients who are positive for the test in the target
population
Part 3 will assess sensitivity of OctavaPink test in an enriched population of women with
dense breasts and negative mammography.
Objectives: To obtain an estimate of sensitivity in women with dense breast tissue and
negative mammography that is broadly consistent with that found in the dense breast
population (but not necessarily negative mammogram) in Parts 1A and 1B.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |